Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 25% primary Improvement Relative Risk Ventilation 0% Hospitalization time 20% Abd-Elsalam et al. Ivermectin for COVID-19 RCT LATE Is late treatment with ivermectin beneficial for COVID-19? RCT 164 patients in Egypt Shorter hospitalization with ivermectin (not stat. sig., p=0.085) Abd-Elsalam et al., J. Medical Virology, doi:10.1002/jmv.27122 Favors ivermectin Favors control
Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study
Abd-Elsalam et al., Journal of Medical Virology, doi:10.1002/jmv.27122
Abd-Elsalam et al., Clinical Study Evaluating the Efficacy of Ivermectin in COVID-19 Treatment: A Randomized Controlled Study, Journal of Medical Virology, doi:10.1002/jmv.27122
Jun 2021   Source   PDF  
  All Studies   Meta
RCT 164 hospitalized patients in Egypt showing lower mortality and shorter hospitalization, but without statistical significance. There were no serious adverse effects. Authors suggest the low dosage may have resulted in lower efficacy than other trials, and recommend increased dosage in future trials. For other concerns see []. Time from symptom onset is not specified.
risk of death, 25.0% lower, RR 0.75, p = 0.70, treatment 3 of 82 (3.7%), control 4 of 82 (4.9%), NNT 82, odds ratio converted to relative risk, logistic regression, primary outcome.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 3 of 82 (3.7%), control 3 of 82 (3.7%).
hospitalization time, 19.6% lower, relative time 0.80, p = 0.09, treatment 82, control 82.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abd-Elsalam et al., 2 Jun 2021, Randomized Controlled Trial, Egypt, peer-reviewed, 16 authors, dosage 12mg days 1-3.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Received: 29 May 2021 | Accepted: 31 May 2021 DOI: 10.1002/jmv.27122 RESEARCH ARTICLE Clinical study evaluating the efficacy of ivermectin in COVID‐19 treatment: A randomized controlled study Sherief Abd‐Elsalam1 | Rasha A. Noor2 | Rehab Badawi1 | Mai Khalaf1 | Eslam S. Esmail1 | Shaimaa Soliman3 | Mohamed S. Abd El Ghafar4 | Mohamed Elbahnasawy5 | Ehab F. Moustafa6 | Sahar M. Hassany6 | Mohammed A. Medhat6 | Haidi Karam‐Allah Ramadan6 | Maii A. S. Eldeen7 Mohamed Alboraie8 | Ahmed Cordie9 | Gamal Esmat9 1 Department of Tropical Medicine and Infectious diseases, Faculty of Medicine, Tanta University, Tanta, Egypt | Abstract Researchers around the world are working at record speed to find the best ways to 2 Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt 3 Department of Public health and Community Medicine, Faculty of Medicine, Menoufia University, Menoufia, Egypt 4 Department of Anesthesia, Surgical Intensive Care, and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt 5 Department of Emergency Medicine and traumatology, Faculty of Medicine, Tanta University, Tanta, Egypt 6 Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt 7 Department of Microbiology and Immunology, Tanta University, Tanta, Egypt 8 Department of Internal Medicine, Al‐Azhar University, Cairo, Egypt 9 Department of Endemic Medicine, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt Correspondence Sherief Abd‐Elsalam, Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, El‐Giash St, 31527 Tanta, Egypt. Email: treat and prevent coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin for the treatment of hospitalized mild to moderate COVID‐19 infected patients. This was a randomized open‐label controlled study that included 164 patients with COVID‐19. Patients were randomized into two groups where Group 1 (Ivermectin group) included patients who received ivermectin 12 mg once daily for 3 days with standard care and Group 2 (control group) included patients who received standard protocol of treatment alone for 14 days. The main outcomes were mortality, the length of hospital stay, and the need for mechanical ventilation. All patients were followed up for 1 month. Overall, 82 individuals were randomized to receive ivermectin plus standard of care and 82 to receive standard of care alone. Patients in the ivermectin group had a shorter length of hospital stay (8.82 ± 4.94 days) than the control group (10.97 ± 5.28 days), but this was not statistically significant (p = 0.085). Three patients (3.7%) in each group required mechanical ventilation (p = 1.00). The death rate was three patients in the ivermectin group (3.7%) versus four patients (4.9%) in the control group without any significant difference between the two groups (p = 1.00). Although there was no statistically significant difference in any endpoints by ivermectin doses (12 mg/day for 3 days); there was an observed trend to reducing hospital stay in the ivermectin‐ treated group. KEYWORDS COVID‐19, chloroquine, ivermectin, mortality, treatment 1 | INTRODUCTION in Wuhan City, Hubei Province, China. It was originally reported to the World Health Organization (WHO) on December 31, 2019. The WHO Coronavirus disease 2019 (COVID‐19) is caused by a novel..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop